These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 17409431

  • 1. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation.
    Yang CC, Wang YC, Wei S, Lin LF, Chen CS, Lee CC, Lin CC, Chen CS.
    Cancer Res; 2007 Apr 01; 67(7):3229-38. PubMed ID: 17409431
    [Abstract] [Full Text] [Related]

  • 2. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.
    Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler HP.
    Cancer Res; 2000 Oct 01; 60(19):5494-8. PubMed ID: 11034093
    [Abstract] [Full Text] [Related]

  • 3. Development of small-molecule cyclin D1-ablative agents.
    Huang JW, Shiau CW, Yang J, Wang DS, Chiu HC, Chen CY, Chen CS.
    J Med Chem; 2006 Jul 27; 49(15):4684-9. PubMed ID: 16854074
    [Abstract] [Full Text] [Related]

  • 4. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma.
    Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW, Chen CS.
    Cancer Res; 2005 Feb 15; 65(4):1561-9. PubMed ID: 15735046
    [Abstract] [Full Text] [Related]

  • 5. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
    Nagata D, Yoshihiro H, Nakanishi M, Naruyama H, Okada S, Ando R, Tozawa K, Kohri K.
    Cancer Detect Prev; 2008 Feb 15; 32(3):259-66. PubMed ID: 18789607
    [Abstract] [Full Text] [Related]

  • 6. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.
    Weng JR, Chen CY, Pinzone JJ, Ringel MD, Chen CS.
    Endocr Relat Cancer; 2006 Jun 15; 13(2):401-13. PubMed ID: 16728570
    [Abstract] [Full Text] [Related]

  • 7. PPARgamma ligands suppress the feedback loop between E2F2 and cyclin-E1.
    Komatsu Y, Ito I, Wayama M, Fujimura A, Akaogi K, Machida H, Nakajima Y, Kuroda T, Ohmori K, Murayama A, Kimura K, Yanagisawa J.
    Biochem Biophys Res Commun; 2008 May 23; 370(1):145-8. PubMed ID: 18355447
    [Abstract] [Full Text] [Related]

  • 8. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells.
    Yuan H, Gong A, Young CY.
    Carcinogenesis; 2005 Apr 23; 26(4):793-801. PubMed ID: 15661808
    [Abstract] [Full Text] [Related]

  • 9. 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes inhibit growth, induce apoptosis, and decrease the androgen receptor in LNCaP prostate cancer cells through peroxisome proliferator-activated receptor gamma-independent pathways.
    Chintharlapalli S, Papineni S, Safe S.
    Mol Pharmacol; 2007 Feb 23; 71(2):558-69. PubMed ID: 17093136
    [Abstract] [Full Text] [Related]

  • 10. A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells.
    Wei S, Yang HC, Chuang HC, Yang J, Kulp SK, Lu PJ, Lai MD, Chen CS.
    J Biol Chem; 2008 Sep 26; 283(39):26759-70. PubMed ID: 18650423
    [Abstract] [Full Text] [Related]

  • 11. Methyl 2-cyano-3,11-dioxo-18 beta-olean-1,12-dien-30-oate is a peroxisome proliferator-activated receptor-gamma agonist that induces receptor-independent apoptosis in LNCaP prostate cancer cells.
    Papineni S, Chintharlapalli S, Safe S.
    Mol Pharmacol; 2008 Feb 26; 73(2):553-65. PubMed ID: 17989348
    [Abstract] [Full Text] [Related]

  • 12. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
    Lecomte J, Flament S, Salamone S, Boisbrun M, Mazerbourg S, Chapleur Y, Grillier-Vuissoz I.
    Breast Cancer Res Treat; 2008 Dec 26; 112(3):437-51. PubMed ID: 18204896
    [Abstract] [Full Text] [Related]

  • 13. Thiazolidinediones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor gamma.
    Wei S, Lin LF, Yang CC, Wang YC, Chang GD, Chen H, Chen CS.
    Mol Pharmacol; 2007 Sep 26; 72(3):725-33. PubMed ID: 17569795
    [Abstract] [Full Text] [Related]

  • 14. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
    Yang FG, Zhang ZW, Xin DQ, Shi CJ, Wu JP, Guo YL, Guan YF.
    Acta Pharmacol Sin; 2005 Jun 26; 26(6):753-61. PubMed ID: 15916743
    [Abstract] [Full Text] [Related]

  • 15. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
    Mansour M, Schwartz D, Judd R, Akingbemi B, Braden T, Morrison E, Dennis J, Bartol F, Hazi A, Napier I, Abdel-Mageed AB.
    Int J Oncol; 2011 Feb 26; 38(2):537-46. PubMed ID: 21170507
    [Abstract] [Full Text] [Related]

  • 16. Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells.
    Coyle AT, Kinsella BT.
    Biochem Pharmacol; 2006 Apr 28; 71(9):1308-23. PubMed ID: 16499875
    [Abstract] [Full Text] [Related]

  • 17. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
    Jackson KM, Frazier MC, Harris WB.
    Anticancer Res; 2007 Apr 28; 27(3B):1483-8. PubMed ID: 17595765
    [Abstract] [Full Text] [Related]

  • 18. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth.
    Li M, Lee TW, Mok TS, Warner TD, Yim AP, Chen GG.
    J Cell Biochem; 2005 Nov 01; 96(4):760-74. PubMed ID: 16149072
    [Abstract] [Full Text] [Related]

  • 19. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
    Schiefelbein D, Seitz O, Goren I, Dissmann JP, Schmidt H, Bachmann M, Sader R, Geisslinger G, Pfeilschifter J, Frank S.
    Mol Pharmacol; 2008 Oct 01; 74(4):952-63. PubMed ID: 18599600
    [Abstract] [Full Text] [Related]

  • 20. Inhibitory effect of acetyl-11-keto-beta-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells.
    Yuan HQ, Kong F, Wang XL, Young CY, Hu XY, Lou HX.
    Biochem Pharmacol; 2008 Jun 01; 75(11):2112-21. PubMed ID: 18430409
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.